Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2016 - 2025)

Vanda Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $488.9 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 25.49% to $488.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 9.93% decrease, with the full-year FY2025 number at $488.9 million, down 25.49% from a year prior.
  • Liabilities and Shareholders Equity hit $488.9 million in Q4 2025 for Vanda Pharmaceuticals, down from $601.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for VNDA hit a ceiling of $656.2 million in Q4 2024 and a floor of $488.9 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $614.1 million across 5 years, with a median of $628.3 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 12.38% in 2021 and later decreased 25.49% in 2025.
  • Tracing VNDA's Liabilities and Shareholders Equity over 5 years: stood at $593.8 million in 2021, then grew by 6.81% to $634.2 million in 2022, then rose by 2.24% to $648.4 million in 2023, then increased by 1.2% to $656.2 million in 2024, then decreased by 25.49% to $488.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VNDA at $488.9 million in Q4 2025, $601.1 million in Q3 2025, and $624.7 million in Q2 2025.